Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding, S Puhalla… - Cancer chemotherapy …, 2017 - Springer
Abstract Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …
被引用次数：14 相关文章

Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding, S Puhalla… - Cancer …, 2017 - search.proquest.com
Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine
activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities …
[HTML] nih.gov

[HTML][HTML] PHASE I STUDY OF VELIPARIB IN COMBINATION WITH GEMCITABINE

R Stoller, JC Schmitz, F Ding, S Puhalla… - Cancer …, 2017 - ncbi.nlm.nih.gov
Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine
activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities …

Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding… - Cancer …, 2017 - scholars.northwestern.edu
Background: Veliparib (ABT-888) is an oral PARP inhibitor expected to increase
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …

Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding… - Cancer …, 2017 - einstein.elsevierpure.com
Background: Veliparib (ABT-888) is an oral PARP inhibitor expected to increase
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …

Phase I study of veliparib in combination with gemcitabine.

R Stoller, JC Schmitz, F Ding, S Puhalla… - Cancer …, 2017 - europepmc.org
Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine
activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities …

Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding, S Puhalla… - Cancer Chemotherapy …, 2017 - pure.psu.edu
Background: Veliparib (ABT-888) is an oral PARP inhibitor expected to increase
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …

Phase I study of veliparib in combination with gemcitabine

R Stoller, JC Schmitz, F Ding… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine
activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities …